Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2+ Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT04481113
What this trial is testing

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+17 more
OHSU Knight Cancer Institute 8
Large-scale testing (Phase 3)Not Yet RecruitingNCT07802626
What this trial is testing

Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing

Who this might be right for
HR Positive/HER-2 Negative Breast Cancer
SWOG Cancer Research Network 1,084
Large-scale testing (Phase 3)Study completedNCT02941926
What this trial is testing

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 3,246
Large-scale testing (Phase 3)Looking for participantsNCT05827081
What this trial is testing

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 1,400
Testing effectiveness (Phase 2)Study completedNCT03219476
What this trial is testing

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Who this might be right for
Breast CancerInvasive Breast Cancer
Medical College of Wisconsin 37
Testing effectiveness (Phase 2)Looking for participantsNCT05728268
What this trial is testing

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

Who this might be right for
Breast Cancer
Shantou Central Hospital 64
Not applicableStudy completedNCT04736576
What this trial is testing

Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy

Who this might be right for
Breast Cancer
Pfizer 99
Testing effectiveness (Phase 2)Study completedNCT04796623
What this trial is testing

TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Who this might be right for
HR-positive, HER2-negative Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 122
Testing effectiveness (Phase 2)UnknownNCT05469750
What this trial is testing

Dalpiciclib Plus Letrozole and Capecitabine

Who this might be right for
Advanced Breast Cancer
Fujian Medical University Union Hospital 48
Testing effectiveness (Phase 2)Looking for participantsNCT06611813
What this trial is testing

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07428018
What this trial is testing

Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib

Who this might be right for
Breast CancerHER2 + Breast CancerHR Positive+1 more
Mario Negri Institute for Pharmacological Research 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05431504
What this trial is testing

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Who this might be right for
Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT05625087
What this trial is testing

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Who this might be right for
Breast Cancer Stage IV
UNICANCER 162
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Post-approval studies (Phase 4)Active Not RecruitingNCT05161195
What this trial is testing

Roll-over Study to Allow Continued Access to Ribociclib

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 134
Not applicableEnded earlyNCT04436120
What this trial is testing

Treatment Resistance Following Anti-cancer Therapies

Who this might be right for
Disease Progression
Pfizer 38
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Not applicableStudy completedNCT06344793
What this trial is testing

Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 608
Large-scale testing (Phase 3)Not Yet RecruitingNCT06996093
What this trial is testing

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
Fudan University 2,508
Large-scale testing (Phase 3)Looking for participantsNCT06312176
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,200
Next Page